Lily Chen
Wellness Writer
Younger women into skin, hormones, mental health and fitness
Lily Chen writes about the wellness trends younger readers actually care about — skin, hormones, mental health, gadgets — and runs each one past the research before recommending it. Trend-fluent, evidence-loyal.
Latest articles
What Happens to Your Cholesterol When You Stop Drinking
A massive Japanese cohort study tracked the exact moments adults quit — or started — drinking, and watched their LDL and HDL move in opposite directions.
GLP-1s Beyond Weight Loss: Kidneys, Taste Buds, and What the Real-World Data Actually Show
A multinational cohort sketches who's really starting GLP-1s for diabetes and kidney disease — and a new mouse study hints these drugs may rewire taste itself.
GLP-1s Grow Up: What the Latest Research Says About Weight Regain, Brain Health, and Your Eyes
A cluster of new 2025 papers reframes GLP-1 drugs as long-horizon metabolic tools — with real promise after bariatric surgery, a tantalizing brain-protection signal, and one safety question worth taking seriously.
Beyond Weight Loss: Why GLP-1 Drugs Are Becoming Cardio-Metabolic Workhorses
Semaglutide and tirzepatide started as obesity treatments. A wave of moderate-quality evidence is pushing them toward something bigger — and asking new questions about inflammation, the heart, and even cancer.
Semaglutide's Second Act: Beyond Weight Loss to Liver, Skin, and Inflammation
New 2025 data hints that GLP-1 drugs may quiet inflammation in the liver and skin — but a sober pharmacology review reminds us the price tag, and the science, are still catching up.
Semaglutide in the Real World: New Cohorts, New Molecules, and the Limits of One-Size-Fits-All
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.
After the Shot: What Actually Holds Weight Off When You Stop GLP-1s
A small real-world study suggests older, cheaper anti-obesity pills may help preserve much of the weight loss achieved on a year of GLP-1s — a practical lifeline as access and prices stay volatile.
Semaglutide's Second Act: Kidney Protection, Dosing Gaps, and the Next GLP-1s
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.